Researchers from Cakan Zebrafish Models Laboratory published their latest results on circulating tumor cell targeting capacity of albumin-based drug carrier nanoparticles in the Journal of Drug Delivery Science and Technology.
Serum albumin is the natural carrier of many drug molecules and is widely used in nanoparticle synthesis. Dr. Gülçin ÇAKAN AKDOĞAN, a group leader at IBG,and her team members Esra ERSÖZ GÜLSEVEN and Emine GELİNCİ demonstrated that doxorubicin-loaded serum albumin nanoparticles have the capacity to target and kill circulating breast cancer (MCF7) cells in the zebrafish CTC xenograft model that they have developed. They published their results recently in the Journal of Drug Delivery Science and Technology.
This study is the first one to demostrate the capacity of albumin nanoparticles to target tumor cells outside of tumor tissue.